10x Genomics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade 10x Genomics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About TXG
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics.
CEOSerge Saxonov
CEOSerge Saxonov
Employees1,306
Employees1,306
HeadquartersPleasanton, California
HeadquartersPleasanton, California
Founded2012
Founded2012
Employees1,306
Employees1,306
TXG Key Statistics
Market cap2.30B
Market cap2.30B
Price-Earnings ratio-29.04
Price-Earnings ratio-29.04
Dividend yield—
Dividend yield—
Average volume3.08M
Average volume3.08M
High today$18.31
High today$18.31
Low today$17.06
Low today$17.06
Open price$17.57
Open price$17.57
Volume1.83M
Volume1.83M
52 Week high$20.34
52 Week high$20.34
52 Week low$6.78
52 Week low$6.78
Stock Snapshot
The current 10x Genomics(TXG) stock price is $18.16, with a market capitalization of 2.3B. The stock trades at a price-to-earnings (P/E) ratio of -29.04.
On 2025-12-04, 10x Genomics(TXG) stock traded between a low of $17.06 and a high of $18.31. Shares are currently priced at $18.16, which is +6.4% above the low and -0.8% below the high.
The 10x Genomics(TXG)'s current trading volume is 1.83M, compared to an average daily volume of 3.08M.
During the past year, 10x Genomics(TXG) stock moved between $6.78 at its lowest and $20.34 at its peak.
During the past year, 10x Genomics(TXG) stock moved between $6.78 at its lowest and $20.34 at its peak.
Analyst ratings
67%
of 18 ratingsBuy
33.3%
Hold
66.7%
Sell
0%
People also own
Based on the portfolios of people who own TXG. This list is generated using Robinhood data, and it’s not a recommendation.